Drugdu.com expert's response:

Common issues in pharmaceutical production quality management are generally concentrated in the following areas:

Personnel & Awareness

Quality management in many companies remains at the level of "passing inspections" rather than being truly internalized into production habits. Frontline operators have high turnover, training is superficial, and SOP non-compliance is widespread. The quality department lacks authority and often yields to production when output and quality conflict.

Data Integrity

This is a key regulatory enforcement focus in recent years. Handwritten records are casually altered, electronic data lacks audit trails, abnormal data is deleted without trace, and shared login accounts are common — especially prevalent among small and mid-sized pharma companies. FDA and NMPA requirements on data integrity are tightening, yet many companies' IT systems are still stuck at the Excel stage.

Deviation & Change Control Out of Control

When deviations occur, the first instinct is to find a workaround, not to investigate root causes. Change control is merely for show — equipment parameters changed, process conditions adjusted, production already underway before the change process is completed. CAPA is written but not tracked, and the same issues recur repeatedly.

Weak Supplier Management

Audits of API and packaging material suppliers are superficial — reviewing qualification documents without visiting actual sites. Supplier changes are not fully assessed for quality impact, and incoming inspection is often cut due to cost pressure.

Insufficient Process Validation & Ongoing Verification

Many companies only conduct three-batch validation at registration, with no continuous monitoring post-launch. Process parameter drift goes undetected until non-conforming products appear. This is especially critical for biologics and complex formulations where process sensitivity is high.

Cleanroom Environment & Cross-Contamination Risk

Cleaning validation for shared production lines is inadequate, with incomplete residue testing. Details like gowning, material transfer, and pressure differential management are poorly enforced. Risk assessment for multi-product shared lines is often crude.

Documentation vs. Actual Operations — "Two Sets of Books"

What is written is one thing; what is done is another. "Writing records in advance" or "backfilling after the fact" is an open secret in the industry. Batch records mismatching actual production times, signature forgery, and missing reviews at critical steps — these are the most common findings during unannounced inspections.

Quality Risk Management Becomes a Formality

Tools like FMEA and HACCP are not unknown, but they are filed away after use. Risk assessments are not linked to actual production data and become "write-for-the-sake-of-writing" exercises.

The fundamental contradiction: quality management is treated as a cost center, not a value center. Under the pressure of volume-based procurement and cost competition, many pharma companies treat quality investment as a compressible expense — only to discover, after an incident, that the cost of failure far exceeds the cost of prevention.